Literature DB >> 15686511

Effect of tacrolimus in a patient with pure red-cell aplasia.

S Yoshida1, T Konishi, T Nishizawa, Y Yoshida.   

Abstract

A 78-year-old woman has suffered from pure red-cell aplasia (PRCA) associated with generalized myasthenia gravis and thymoma. Cyclosporin A (CyA) with corticosteroid increased numbers of erythroid cells in her bone marrow cells but she required monthly blood transfusions. Administration of tacrolimus as a substitution for CyA inhibited progression of anemia without the need for further blood transfusion. No serious side effects were observed. This case demonstrates that tacrolimus is another option of treatment for PRCA in patients who fail to respond to CyA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15686511     DOI: 10.1111/j.1365-2257.2004.00654.x

Source DB:  PubMed          Journal:  Clin Lab Haematol        ISSN: 0141-9854


  6 in total

Review 1.  Pure red cell aplasia.

Authors:  Robert T Means
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

2.  Pure red cell aplasia induced by anti-erythropoietin antibodies, well-controlled with tacrolimus.

Authors:  Koji Hashimoto; Makoto Harada; Yuji Kamijo
Journal:  Int J Hematol       Date:  2016-06-23       Impact factor: 2.490

3.  How I manage acquired pure red cell aplasia in adults.

Authors:  Carmelo Gurnari; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2021-04-15       Impact factor: 22.113

4.  [How I diagnose and treat pure red cell aplasia].

Authors:  B Han
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-01-14

5.  Rational management approach to pure red cell aplasia.

Authors:  Suresh Kumar Balasubramanian; Meena Sadaps; Swapna Thota; Mai Aly; Bartlomiej P Przychodzen; Cassandra M Hirsch; Valeria Visconte; Tomas Radivoyevitch; Jaroslaw P Maciejewski
Journal:  Haematologica       Date:  2017-12-07       Impact factor: 9.941

6.  Effective treatment of refractory acquired pure red blood cell aplasia with eltrombopag and sirolimus: a case report.

Authors:  Yuzhou Huang; Xianyong Jiang; Bing Han
Journal:  Ther Adv Hematol       Date:  2020-07-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.